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ABSTRACT 
The discovery of the microbe Shigella was dated back about 100 years ago by a 
scientist named Kiyoshi Shiga. Virulent Shigella spp. are known to cause bacillary 
dysentery (shigellosis) in humans which is characterized by the passage of bloody 
stools. According to the WHO, an estimated of 1.1 million global population dies every 
year is due to the disease shigellosis. Despite much studies were carried out regarding 
this pathogenic bacteria, no vaccine is available for this infectious disease. Literatures 
have postulated that one of the virulence genes is the apy gene which encodes for 
apyrase. Therefore, in this study the gene of interest is the apy gene. We have 
successfully mutated the apy gene with a kanamycin gene cassette (aphA) and 
subcloned the construct into a conjugative suicide vector. The use of this antibiotic gene 
cassette is to facilitate the process of manipulating the genes as it serves as a selective 
marker. The creation of the construct (apy::aphA) is to facilitated the approach into the 
development of a potential vaccine strain of Shigella; as literatures have indicated that 
apy gene is one of the virulence genes. Furthermore, mutation of the virulence genes has 
been proven to be highly immunogenic and safe. 
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ABSTRAK 
Microorganisma Shigella telah ditemui sejak lebih kurang 100 tahun yang lalu 
oleh seorang saintis bemama Kiyoshi Shiga. Bakteria Shigella telah dikenalpasti dimana 
ia mengakibatkan diarhea berdarah (bacillary dysentery). Penyakit yang dijangkiti oleh 
microorganisma ini dikenali sebagai "shigellosis". Menurut WHO (World Health 
Organization), lebih kurang 1.1 juta nyawa terkorban setiap tahun akibat penyakit 
tersebut disekitar dunia. Walaupun banyak penyelidikan mengenai bacteria patogenik 
ini, sehingga kini masih tiada vaksin untuk penyakit berjangk.it ini. Ahli saintis telah 
mengenapasti yang salah satu gen virulen adalah gen apy yang mengekodkan enzim 
apyrase. Dengan demikian, tujuan projek ini adalah tertumpu kepada gen apy ini. Kami 
telah melakukan mutasi (insertional mutation) kepada gen apy ini dengan kaset gen 
kanamycin (aphA). Tujuan perlaksanaan mutasi dengan kaset tersebut adalah untuk 
menyenangkan proses pengenalpastian ldon-ldon yang mengalami mutasi daripada yang 
lain. Konstrak yang telah direkakan ini dapat menyumbang kepada penghasilan satu 
strain vaksin yang berpotensi untuk menywnbangkan imuniti terhadap bakteria Shigella 
ini. Tambahan pula, banyak penyelidikan telah menunjukkan kerberkesanan mutasi gen 
virulen dengan penghasilan vaksin yang imunogenik serta selamat untuk: manusia. 
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1.0. INTRODUCTION 
1.1. Shigella & Shigellosis 
The microbe Shigella was discovered about 100 years ago by a scientist named 
Kiyoshi Shiga. Shigella is a small, gram-negative, encapsulated, non-motile, non-
lactose fennenting bacterium that is bile salts resistant. In addition, unlike other 
bacterial pathogens Shigella is less susceptible to acid Shigella is very infectious in 
which its infectious dose is 10-200 organisms by ingestion; partly this is due to the 
ability of the organism to survive the transit through the stomach (DuPont HL et al., 
1989). In addition, researchers have found that many strains of Shigella produce a toxin 
called "shiga toxin" which is very potent and destructive. Shiga toxin is very similar to 
the verotoxin of E. coli 0157:H7. Shigellajlexneri is a human intestinal pathogen that 
invades the epithelium of the colon; the invasion causes symptoms like fever which is 
similar to other invasive bacterial pathogens, enteric viruses, and cytotoxic organisms 
(DuPont HL, 1997). The disease cause by this virulent bacteriwn is called shigellosis, 
which is also known as classical bacillary dysentery. 
Shigellosis is characterised by the frequent and painful passage of stools that 
consist largely of blood, mucus and pus, accompanied by fever and stomach cramps. At 
present, shigellosis can be treated with antibiotics; ampicillin, trimethoprim, or 
ciprofloxacin At present, there is no vaccine available to prevent shigellosis. However, 
active research and studies into the development of Shigella vaccine are currently in the 
progress. 
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1.2. Epidemiology, pathogenesis and Shigella outbreak 
Shigella is a highly contagious bacterium that causes bacillary dysentery. This 
genus consists of 4 species; S. dysenteriae, S. jlexneri, S. boydi~, and S. sonnei. All four 
species of Shigella cause disease in humans. The disease process involves invasion of 
colonic mucosal cells and induction of an intense inflammatory response, leading to the 
death of epithelial & immune cells and the fonnation of colonic mucosal ulcerations and 
abscesses. Shigellosis is an endemic throughout the world. It causes about 1.1 million 
deaths every year globally. To date, there are approximately 164.7 million cases world 
wide (WHO 2002). There may be many go unreported as only mild symptoms is 
involved while some have no symptoms at all. S. sonnei is predominantly isolated from 
patients of developed countries; S. flexneri 2a is predominantly found in developing 
countries; while S. dysenteriae is predominantly isolated in underdeveloped countries. 
This contagious organism is spread by direct or indirect contact with infected 
individuals. Salads (potato, tuna, shrimp, macaroni, and chicken), mw vegetables, milk 
and dairy products, and poultry; contamination of these foods is usually through the 
fecal-oral route. Fecally contaminated water and unsanitary handling by food handlers 
are the most common causes of contamination. Shigella often causes outbreaks in 
daycare centers. Parents often acquire the illness from their children. Symptoms 
manifestation of Shigella inc1ude diarrhea which may be mi1d or severe, a1ong with 
fever and nausea. The diarrhea may be watecy or bloody. Vomiting and abdominal 
cramping may also occur. However, some infected people may not show any symptoms. 
Shigella infection is generally limited to the intestinal mucosa therefore bacteremia due 
to Shigella is extremely rare (Morduchowicz G et a/., 1987; Struelens MJ et a/., 1985). 
Shigel!a rarely occurs in animals; principally a disease of humans except other primates 
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such as monkeys and chimpanzees. The organism is frequently found in water polluted 
with human feces. 
Although several Gram negative enteric pathogens are able to penetrate 
mammalian cells (including Salmonella, certain strains of Escherichia coli, and 
Yersinia), only Shigella and enteroinvasive E. coli escape from the phagocytic vacuole 
and utilize proteins of the host cell cytosol in the pathogenic process. Once in the 
intestinal tract of the hwnan ho~ Shigella jlexneri directs its own uptake into the 
co1onic mucosa through membrane ruffling and macropinocytosis in a manner simi1ar to 
Salmonella uptake (Adam T eta/., 1995; Clerc Petal., 1987). After engulfinent, the 
bacterium is surrounded by a membrane-bound vacuole within the host. However, the 
bacteriwn rapidly lyses the surrounding vacuole and is released into the cytosol, where 
it grows and divides (Sansonetti PJ eta/., 1986). Once the microbe has escaped from the 
vacuole, it quickly becomes coated with filamentous actin and ultimately forms an actin 
tail at one pole of the bacterium (Bernardini ML et al., 1989; Ogawa H et a/., 1968). 
This actin polymerization propels the bacterium through the cytoplasm at speeds 
approximately 0.4 f.unlsec (Zeile WL et a/., 1996). When the pathogen reaches the 
plasma membrane, it fonns a long protrusion into the neighboring cell, which 
subsequently internalizes the microbe (Kadurugamuwa JL eta/., 1991). The bacterium 
again breaks out of the vacuole, thereby starting a new cycle of infection in a new host 
cell (Allaoui A eta/., 1992). This process allows Shigella to move from cell to cell 
without ever contacting the extracellular milieu. 
Outbreaks of infection are common and usually occur in schools and institutions 
where people are in close contact. It has been suggested that in developing countries 
flies may spread the infection from person to person, as the disease is commonest at the 
time of year when the fly population is highest. Worldwide, there are about 165 million 
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cases of shigellosis a year and 1.1 million deaths, according to the World Health 
Organization. Outbreaks have been reported in men who have sex with men; under 
conditions of crowding; and where personal hygiene is poor, such as in jails, institutions 
for children, day-care centres and mental hospitals. Usually, more than one serotype is 
present in a community; occasionally mixed infections with other intestinal pathogens 
are seen (CDC, 2001). In recent years, multiple-antibiotic-resistant Shigella has 
surfaced in all areas of the world (CDC, 2001 ). The widespread use of antimicrobial 
drugs is often re1ated in mu1tip1e drug resistant strains of bacteria 
According to the World Health Organization, 580,000 cases of shigellosis are 
reported among travellers from industrialized countries. A total of 69% of all episodes 
and 61% of all deaths attributable to shigellosis involve children less than 5 years of 
age. Since the late 1960s pandemic waves of Shigella dysentery have hit Central 
America, South and Southeast Asia and sub-Saharan Africa, often striking areas of 
political upheaval and natural disaster (WHO 2002). 
1.3. Diagnosis of shigellosis 
Diagnosis of a Shigella infection depends on a great deal microbiologic culture 
and sensitivity testing. Even though clinical presentation of the patient may evoke 
suspicion of shigellosis but the diagnosis solely relies on the isolation and identification 
of the bacterium from the feces or rectal swabs in the labomtory. Patients presenting 
with watery diarrhea and fever should be suspected of having shigellosis. Although 
blood is common in the stools of patients with amebiasis, it is usually dark brown rather 
than bright red, as in Shigella infections. Microscopic examination of stool smears from 
patients with amebiasis should reveal erythrophagocytic trophozoites in the absence of 
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PMN, whereas bacillary dysentery is characterized by sheets of PMN. Isolation of 
shigellae in the clinical laboratory typically involves an initial streaking for isolation on 
differential/selective media with aerobic incubation to inhibit the growth of the 
anaerobic normal flora. Commonly used primary isolation media include MacConkey, 
Hektoen Enteric Agar, and Salmonella-Shigella (SS) Agar. These media contain bile 
salts to inhibit the growth of other Gram-negative bacteria and pH indicators to 
diflerentiate lactose termenters (Colitorms) from non-lactose termenters such as 
shigellae. Following an overnight incubation, non-lactose fermenting colonies are 
streaked and stabbed into tubed slants of Triple Sugar Iron Agar. In this differential 
media, Shigella species produce an alkaline slant and an acid butt with no bubbles of 
gas in the agar. Tllis reaction gives a presumptive identification, while slide 
agglutination tests with antisera for serogroup and serotype confirm the identification. 
This is usually accomplished using commercially available, absorbed rabbit antisera 
slide agglutination tests. 
Figure 1. I.: Microscopic view of the infectious microbe Shigel/aflexneri. 
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1.4. Treatment 
Regardless of the causative agents, treatment of diarrheal diseases is mainly to 
correct the abnonnalities that result from isotonic dehydration, metabolic acidosis, and 
significant potassium loss though shigellosis seldom causes severe dehydration. 
Therefore the mainstay of treatment for shigellosis is the oral rehydration treatment 
developed by the World Health Organization which has been proven effective and safe 
in the treatment of acute diarrhea, provided that the patient is not vomiting or in shock 
from severe dehydration. With proper hydration, shigellosis is generally a self-limiting 
disease, and the decision to prescribe antibiotics is dependant on the severity of disease, 
the age of the patient, and the likelihood of further transmission of the infection. Some 
studies found that antimicrobial therapy is unnecessary unless to prevent further 
transmission. However, clinically it is found that effective antibiotic treatment reduces 
the average duration of illness from approximately one week to approximately 3 days 
and also reduces the period of Shigella excretion after symptoms subside. Absorbable 
drugs such as ampicillin (2 glday for 5 days) are likely to be effective when the isolate 
is sensitive. Trimethoprim (8 mglkg/day) and sulfamethoxazole (40 mglkglday) will 
eradicate sensitive organisms quickly from the intestine, but resistance to this agent is 
increasing. For the resistant strain, ciprofloxacin (1 g/day for 3 days) is effective against 
multiple drug resistant strains, but this antibiotic is not approved by the United States 
Food and Drug Administration (FDA) for use in children less than 17 years of age due 
to the risk of cartilage damage. Multiple drug resistant strain of Shigella is common in 
Manitoba, Canada; especially to cotrimoxazole, thus the antibiotic choice should be 
based on culture and sensitivity test results (CDC 200 I). 
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1.5. Control measures & prevention 
As for the control measures of the infected patients, education on the importance 
of proper hand wash and personal hygiene is essential in preventing further 
transmission. Infected patients should not provide food, child, and patient care until two 
consecutive stool cultures (collected 24 hours apart or 48 hours after antibiotic treatment 
has ended) are free of Shigella (CDC 2001 ). As a general prevention guideline for the 
public, proper personal hygiene education is very important in curbing fecal-oral-
transmitted diseases. Other preventative measures are proper sanitary disposal of feces 
and toilet waste, drinking of safe and clean water supply, control of flies (may be the 
intermediate host), cleanliness in preparing and handling of food and milk, and 
breastfeeding for the infants as it provides good immunity to the newborns. 
Theoretically, this communicable disease can be curbed if proper preventative measures 
are undertaken. However, in recent years multiple drug resistant strains of such 
organisms have stirred the interest amongst scientists to a deeper approach into the 
development of effective vaccines and drugs. 
1.6. Vaccine candidates under development 
In contrast to other more established diseases like cholera and typhoid fever, 
there are no licensed vaccines currently available for shigellosis. Until recently, 
scientists have carried out vaccine development in search of Shigella vaccines. 
Candidate vaccine strains have been developed in many research laboratory facilities. 
However, as of present none has been approved by any federal agency. 
In search of the shigellosis vaccines, two approaches have been undertaken for 
the development: I) live attenuated bacteria with genetically engineered mutations in a 
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virulence gene (icsA) and/or a synthetic pathway gene (iuc, ent, aroA, aroD, guaBA); 
and 2) subunit vaccines that elicit antibody responses against the 0-specific 
polysaccharide component of the LPS. Scientists at the Institut Pasteur have developed 
live-oral vaccine candidates against Shigella jlexneri 2a (SC602) and against Shigella 
dysenteriae type 1 (SC599) by creating precise mutations in the icsA (or virG) gene, 
which is a virulence plasmid gene encoding a 120 mDa outer membrane protein; the iuc 
and ent genes, which are related to a chromosomal locus encoding aerobactin and 
enterocho1in; and stxA gene, which encodes the A subunit of Shiga toxin. The 
advancement in molecular biology has enabled extensive development of the live 
attenuated oral vaccine candidate. The SC602 vaccine candidate has been tested in 
Phase 1 and 2 studies in North American adult volmtteers in which they are given a 
single dose of l 04 cfu. The findings are positive; that is not only does the vaccine 
candidate proved high immunogenic but also safe for oral dose. 
Another Shigella vaccine candidate in the development by Kotloff et al., 1999; 
known as CVD1207, is a live attenuated Shigella jlexneri 2a vaccine candidate with 
specific deletion mutations in virG, sen, set, and guaBA. The vaccine candidate CVD 
1207 strain still has the ability to invade epithelial cells but cannot effectively spread 
intercellularly after invasion (llvirG), does not produce enterotoxin (llsen and llset), and 
has limited proliferation in vivo (llguaBA). In this research work, Kotloff eta/. have 
successfully produced the CVD 1207 strain which is highly attenuated in humans. Other 
than the CVD 1207 and SC602 strains, another vaccine candidate strain that is currently 
under developmental progress is the SFL 124 (Serotype Y). It is said to be a promising 
live oral vaccine candidate, which has been shown to be safe and immunogenic in 
human volunteers. To change the serotype of this vaccine strain, Guan and Verma, 1998 
inserted a serotype conversion gene cluster into the chromosome of SFL 124 by using a 
- 10-
bacteriophage-based site-specific integration system. By cloning an integrase gene ( int), 
an attachment site ( attP) and a glucosyl transfer gene cluster from bacteriophage SfX 
into a suicide vector, and subsequently introducing this construct into S. jlexneri 
SFL124, Guan and Verma, 1998 obtained aS. jlexneri strain (designated SFL1213) 
expressing the serotype X somatic antigen specificity. 
1. 7. The importance of Apyrase gene 
Many studies & research have shown that one of the major virulence factors is 
the apyrase gene (Bhargava et al., 1995, Babu et al., 2002, Santapaola et al., 2002). The 
presence of a nucleoside triphosphate hydrolyzing activity of S. jlexneri is catalyzed by 
the enzyme apyrase (ATP cliphosphohydrolase). The enzyme apyrase has the ability to 
sequentially hydrolyze nucleoside triphospha.tes to corresponding diphospha.tes and then 
monophosphates. Babu et al. reported that Shigella apyrase acts on both organic and 
inorganic pyrophosphates and does not require metal ions. Having such characteristics, 
Babu eta/. suggested that apyrase is a novel cytotoxin that indiscriminately hydrolyzes 
cellular NTPs and helps Shigella take control of the host cells. Furthermore, its activity 
is also seen in actin polymerization (Babu eta/., 2002). This has suggested that perhaps 
the apyrase has a role in the rate of actin polymerization which is essential for the 
intracellular spread of the bacterium. From the above citations of many researchers, 
apyrase encoded by the apy gene is indeed a virulence associated gene found in the 
megaplasmid as well as in the genome of the Shigellajlexneri. To date, no studies have 
been done in the mutation of the apy gene. Therefore, whether or not a apy-mutated s. 
jlexneri strain will still elicits similar pathogenicity as the wild type still remains 
debatable. 
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2.0. LITERATURE REVIEW 
Bacillary dysentery in humans is often caused by the virulent Shigella spp. or 
the enteroinvasive Escherichia coli (EIEC). Since the advancements of molecular 
biology, extensive studies of the virulence genes associated with the pathogenesis of 
Shigella spp. have been carried out by scientists through out the world. While all these 
studies have led to a better understanding of the overall pathogenesis by the bacteria, 
little is known regarding the biochemical basis of the cytotoxicity by Shigella 
(Bhargava eta/., 1995). 
Studies have found that virulent Shigella codes for the soluble apyrase. The 
apyrase is found to be expressed in all the four species of Shigella and EIEC. 
Experiments and studies done by Bhargava et a/. ( 1995) have pointed out that invasion 
caused by virulent S. jlexneri were indicative of a disruption of cellular respiration and 
fermentation. These findings were carried out an invasion assay using J774 
macrophages as the host. A rapid decrease in the intracellular concentration of 
adenosine triphosphate (ATP), an increase in pyruvate and a decrease in lactate 
concentration were observed in J774 macrophage cells invaded by virulent S. jlexneri. 
In the study, Bhargava et al. have identified the protein responsible for the ATPase 
activity of Shigella; A TP diphosphohydrolase or apyrase. Apyrase is a 25kDa enzyme 
that catalysed the hydrolysis of both A TP and ADP to AMP through sequential release 
of inorganic phosphate (Pi). The enzyme was found to be active in the presence of high 
concentration of EDTA and this indicated that it did not require divalent metal ions for 
its activity. On the other hand, the activity is inhibited by various divalent cations. 
Bhargava eta/. also reported that the apyrase enzyme has the highest activity between 
pH 7.0 and 7.5. However, at temperature 30oC or at 42°C the activity is greatly reduced. 
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This is the temperature at which Shigella phenotypically behave as non-virulent 
bacteria. 
Another study by Babu et al. (2002) revealed that the virulence-associated A TP 
diphosphohydrolase (apyrase) activity of Shigella was found to be similar to bacterial 
non-specific acid phosphatases in primary structure up to as high as 73% similarity. In 
this study, Babu and colleagues obtained the 3D structure of Shigella apyrase by 
threading using Swiss-Model with EBPase as PDB template. However, bacterial 
phosphatases such as acid phosphatase of Escherichia hlattae are predominantly a 
phosphatase whilst Shigella apyrase showed negligible phosphatase activity. According 
to Babu et a/., given the account that Shigella apyrase has no significant phosphatase, 
haloperoxidase, peroxidase, or catalase activities, it should be classified as a new variant 
in the bacterial acid phosphatase family; exo-pyrophosphatase. Distinct from other 
known bacterial pyrophosphates, Babu et a/. reported that Shigella apyrase acts on both 
organic and inorganic pyrophosphates and does not require metal ions. Having such 
characteristics, Babu et a/. suggested that apyrase is a novel cytotoxin that 
indiscriminately hydrolyzes cellular NTPs and helps Shigella take control of the host 
cells. Similar to other bacterial acid phosphatase, Shigella apyrase has a poly-proline 
sequence. The actual significance of the poly-proline region is not well understood in 
Shigella. However, previous study by Niebuhr et a/. ( 1997) has indicated that the poly-
proline region may have interactions with actin. Coincidently, very intense actin 
polymerization activities are central to Shigella's pathogenesis. Actin polymerization, 
also known as treadmilling; is essential for the organisms in intracellular spread. 
Therefore, Shigella apyrase mght be involved in modulating actin polymerization rates 
(Babu et al., 2002). 
- 13-
In a study on the expression of the virulence plasmid carried genes, Berlutti et 
a/. (1998) found that the expression of the apy gene was temperature regulated which is 
similar to other virulence genes. To determine whether the expression of apyrase was 
controlled by temperature at the transcriptional level, Berlutti et a/. performed a 
northern hybridization and dot blot analysis of total RNAs from strains grown at 30 and 
37°C with a 627bp PCR product of internal fragment (coding region) of the apy gene as 
a probe. The RNA blot results demonstrated that the transcription of apy was strictly 
regulated by temperature. They found that it was 12-f~Jd higher at 37°C than at 30°C. 
This has led them to further study the possibility of the apy gene expression is under the 
regulation ofH-NS, and VirF & VirB regulatory cascade. In this experiment, Berlutti et 
a/. assayed sonic extracts and perfonned RNA blot analysis of the llhns deletion 
derivative strains; HN680 & HN280/32 and a piNV-intergrated derivative of wild-type 
EIEC. They then found that the apy gene expression is negatively regulated by H-NS, 
and VirF & VirB regulatory cascade at the transcriptional level. The findings on the 
regulatory mechanisms of the apy gene by Berlutti et al. have strongly suggested that 
the expression of apyrase may be important, especially when bacteria are inside 
susceptible host cells, probably during the phase of intracellular multiplication. 
Previous studies have suggested and indicated that the expression of the 
virulence-plasmid (piNV)-carried potential pathogenesis associated apy gene is 
regulated by the same regulators that govern the expression of virulence genes. These 
findings have led a group of scientists (Santapaola et a/., 2002) into sequencing an 
8032bp Pstl fragment of the piNV ofEIEC strain HN280, in which it encompasses the 
apy gene as well as the adjacent genes. In this study, the methods used involved 
Northern hybridization, RT-PCR, sequence analyses, and primer extension experiment. 
Data & results obtained from these experiments have indicated that ospB and apy genes 
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are co-transcribed as a 2kb bicistronic, temperature regulated mRNA from an upstream 
promoter that precedes ospB. The ospB gene encodes a secreted protein of unknown 
activity and is located immediately upstream of the apy gene. In their study, they have 
also found that sequences resembling promoter elements were not found in the DNA 
region upstream of the 5' end of apy. Furthennore, data findings were consistent with 
their hypothesis of an ospB-apy bicistronic transcript starting from a promoter located 
upstream of ospB. These have led to their postulation that the lkb transcript encoding 
apy alone must have result from post-transcriptional processing of the 2kb transcript at 
the identified 5' end, within the 328bp ospB-apy intercistronic region. In addition, the 
ospB and apy genes are expressed from a single transcript and located in a highly 
conserved DNA region in both Shigella and EIEC have indicated that such a gene 
organization perhaps provide certain advantages to the organisms over the others. 
lkb 
probe ..!!.. .!!! I 
mRNA 
traiiiCripts 
Figure 1.2.: Genetic and transcriptional organization of the ospB-apy operon. 
Psd 
I 
The study of the apy gene found in all the literatures have postulated that apy is 
a potential pathogenesis-associated gene, located on the piNVs of virulent Shigella spp. 
and related EIEC strains (Berlutti eta/., 1998; Bbargava eta/., 1995; Buchrieser et al., 
2000; Venkatasen eta/., 2001). It is also strongly suggested by Berlutti et al. (1998) that 
the expression of apyrase may be essential especially when the bacteria are within the 
susceptible host cells during multiplication. The apy gene has been strongly indicated as 
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one of the virulence genes. However, questions like whether the periplasmic apyrase 
acts as a generalized cytotoxin, is involved in the utilization of exogenous nucleotides 
which mush be dephosphorylated to nucleosides to cross the impermeable cytoplasmic 
membrane, or does it play a role in some unknown bacterial metabolic functions that are 
not directly involved in the pathogenesis is still a mystery. 
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2.1. Lacunae in the literature 
The apy gene was discovered recently as one of the major virulence genes that is 
present within the genome and the megaplasmid of the virulent Shigella (Bhargava et 
a/., 1995). Many studies have also cited the pathogenicity role of the apyrase encoded 
by the apy gene. According to Bhargava et al. (1995), the apyrase of Shigella may be a 
general cytotoxin involved directly or indirectly in the actual killing of the host cells. 
Therefore, the mutation of this apy gene seems to be a promising method of producing a 
highly immunogenic yet safe vaccine candidate. Furthermore, the apy gene is expressed 
in aU the four species of Shigella. This has postulated the possibility of producing a 
vaccine that produces high immunogenicity against all the four species. 
Although the roles of the pathogenicity of the apy gene are established, up to 
date there is no published work on the mutation of this apy gene. Researchers currently 
working on producing the potential vaccine strains for Shigella are targeting at other 
virulence genes, such as the icsA gene. 
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3.0. OBJECTIVES 
• To clone the apyrase gene of S. jlexneri into pTZ57R plasmid. 
• To clone the Kanamycin gene cassette (aphA) from pTOPO 2.1 
• To mutate the apyrase gene by insertional mutation with Kanamycin gene 
cassette (aphA ). 
• To subclone the mutated Apy::aphA into a conjugative suicide vector, pWM91. 
• To screen the successful construct by PCR method and DNA sequencing. 
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4.0. MATERIALS AND :METHODS 
4.1. Materials 
•:• Shigella jlexneri SH043 strain 
•:• E. coli host 
• TOPlO (FmerA LJ(mrv lt.WRMS 
mcrBC)¢80/acZLi\115 &ac X74 deOR 
recAlaraD139 I!J(ara-/eu)1691 ga/U 
ga/KrpsL(stll) endA1 nupG) 
• DH5a A. ptr <F-1>80d lacZll 
miSI:J.(/acZYA-argF) U169 deOR recAJ 
endAl hsdR11 (lk-. mt }phoA ~uppE44 
thi-1 gyrA96 re/Al) 
•:• P1asmid 
• pCRTOP02.1 
• pTZ57R 
• pWM91 
•:• Resrtiction Enzymes 
• KspA1 (Hpai) 
• Saci 
• san 
• Smal 
•!• apy Forward & Reverse primers 
·:· 
·:· 
·:· 
·:· 
•!• 
•!• 
Kanamycin (aphA) Forward 
Reverse primers 
Plasmid extraction kit 
PCR thermal cycler 
Agarose gel electrophoresis 
Luria Bertani 
• Agar 
• Broth 
Antibiotic 
• Ampicillin 
• Kanamycin 
Table 4.1. List of materials used 
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4.2. Experiment overview 
Simulation of the insertional mutation using aphA gene amplified from pTOP02.1 plasmid 
vector using Vector NU 
Verification of the apy gene insert within tbe 
pTOP02.I-apy cloning vector by PCR screening. 
~~ 
PCR amplification of apy gene from PCR amplification of aphA gene cassette 
pTOP02.1-apy nod subclone onto a from pTOP02.1 vector and subclone onto 
pTZ57R cloning vector. a pTZ57R cloning vector. 
--------------. .-----------
Construction of tbe insertional mutation with the aphA gene cassette 
onto linearized pTZ57R-apy. 
~ 
Verification of the mutated apy::ap/IA. insert within the 
pTZ57R cloning vector by PCR screening. 
"Popping out" the construct (apy::aphA) and subclone onto a 
conjugative suicide vector; pWM91 at Smal and Sacl sites. 
Verification of the construct (apy::aphA) within the pWM91 cconjugative 
suicide vector by PCR screening. 
Verification of the apy gene insert within the 
pTZ57R cloning vector by PCR screening. 
r----=--~- -----------. 
PCR screening for the orientation of the 
apy::apllA const ruct using different sets of 
primers. 
Sent for DNA sequencing for the construct 
apy::aphA for verification and 
confirmation. 
Figure 4. 1.: Experiment overview 
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4.3. Methods 
4.3.1. Virtual cloning using Vector NTI 
By using the famous bio-infonnatic application such as the Vector NTI ver. 9.0, 
I was able to manipulate the sequence profile obtained very efficiently and conveniently 
on the computer. This versatile application serves as a database manager for a large data 
or collection of protein and nucleic acid sequence profiles. Many functions can be 
simulated using this software, for example oligonucleotide designing, locating of certain 
genes, identification of unique restriction enzymes recognition sites, gel electrophoresis 
and many more. 
In this study, the Vector NTI was used to identify the unique restriction enzyme 
site in the Shigella j/exneri apy gene. Using the Vector NTI, we simulated the analysis 
of restriction enzyme sites of the apy gene by using some of the more commonly used 
restriction enzymes. The restriction pattern of apy gene was examined to identify the 
unique restriction enzyme which restricts the apy gene somewhere in the middle of its 
open reading frame while not restricting the vector (pTZ57R). After which, an 
insertional mutation simulation was done using the software. The aphA gene sequence 
was obtained from pTOP02.1 vector, in which it's then used to introduce the insertional 
mutation into the apy gene. The aphA gene which confers kanamycin resistant serves as 
a selective marker to facilitate the selection of successful clones. 
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4.3.2. Media preparation 
4.3.2.1 SOB medium 
Contents Amount I volume 
Tryptone 20g 
Yeast extract 5g 
Sodium chloride 0.5g 
Potassium chloride (250mM) lOml 
Deionized distilled water 750ml 
Table 4.2./ngredientsfor preparation of SOB medium. 
The dry ingredients were added into 750 ml of deionized distilled water and the 
pH was adjusted to 7.0 using lN HCl/ 1M NaOH. The volume was made up to 990 ml 
with deionized distilled water. The medium was sterilized by autoclaving at 121°C for 
15 minute and stored at room temperature (21-23°C). Just before use, 10 ml of sterile 
1M magnesium chloride solutions was added to 990 ml of the medium. 
4.3.2.2. SOC Medium 
Contents Amount I volume 
SOB medium lL 
D-Glucose (1M) 20ml 
Table 4.3. Ingredients for preparation of SOC medium. 
Sterile solution of glucose was added to SOB medium and the medium was used 
immediately. 
4.3.2.3. Luria Bertani (LB) agar 
To prepare a 500 mL volume of Luria bertani (LB) agar, 7.5g of tryptone 
(Merck), 2.5g of yeast extract (Oxoid), 5.0g of sodium chloride (Amresco ), and 7.5g of 
agar ( Amresco) are the ingredients required. The first 3 ingredients are first dissolved in 
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about 300 mL of deionized distilled water and stirred well. The agar is poured into a 
separate bottle without adding water. As the 3 ingredients are dissolved top up the rest 
of the deionized distilled water to reach the final volume of 500 mL and stir until all the 
ingredients are completely dissolved. After that, the pH was adjusted to 7.0 by either 
adding drops of IM sodium hydroxide or 1M hydrochloric acid to reach the neutral pH. 
Then, the mixture was poured into the bottle containing the agar powder and sent for 
autoclaving ( 121 oc, 15 minutes, 1 atm ). After the autoclaving process, the media agar 
was Jet cool down to approximately 40°C (before solidifying) before the addition of any 
antibiotic to prevent denaturation of the antibiotic. Then the media agar was poured into 
clean, sterile Petri plates with approximately 25 mL in volume each. The plates are left 
in room temperature for solidifying and can be kept in the cold room for about a month. 
4.3.3. Concentration of antibiotics 
In this research study, only 2 antibiotics were used; ampicillin and kanamycin. 
These antibiotics were used for the isolation and presumptive identification of 
successful clones depending on the antibiotic resistant genes carried on the plasmid 
backbone or the insert. The addition of the antibiotics in the media agar has to be within 
the concentration required to provide effective isolation of sensitive and resistant strain. 
Antibiotics Final concentration 
Ampicillin 100 llg I ml 
Kanamycin 50 11g I ml 
Table 4. 4.: Concentration of antibiotics used m LB agar and LB broth 
-23-
4.3.4. Restriction enzyme digestion 
4.3.4.1. Restriction endonucleases 
Restriction endonucleases (REases ), are very important tools in studies of many 
fields of molecular genetics and molecular biology. This is due to their high specificity 
and ease of use in molecular work. These restriction enzymes are sometimes known as 
the molecular scissors. Without these restriction enzymes, the spectacular advances in 
molecular genetics over the past two decades could not have taken place (Sharma et al., 
2003). Among the different c1asses of restriction enzymes (types l, ll, lll, and IV), Type 
II have been found to have extensive applications in molecular biology (Sharma et al., 
2003 ). To date, more than 3500 type II REases, exhibiting 241 different specificities 
have been isolated. These enzymes are isolated from bacteria in which they serve as a 
detense mechanism against viral infection. As the particular sequence occurs along the 
chromosome, the enzyme cleaves the sugar phosphate backbones of DNA and produces 
fragments. The restriction enzymes used in this study were obtained from Fermentas, 
USA as shown in Table 2 below: 
Restriction (,1eavage site Optimal Optimal 
enzymes buffer temperature 
Hpa I (Ksp At) 5' ... GTI!AAC ... 3' BufferB 37°C 3' ... CAA TTG ... 5' 
Sac I 
5' ... ~GCTIC ... 3' 
3'... CGAG ... 5' Buffer Sac! 37°C 
Sal I 
5' ... ~···3' 
3' ... CAGC ... 5' BufferO 37°C 
Smai 
5' ... ~GGG ... 3' 
3'... ccc ... 5' Buffer Tango 30°C 
Table 4.5.: Restriction enzymes used in this study 
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